PATIENTS | TheraCIM Highlights
TheraCIM (Nimotuzumab) is a monoclonal antibody used for the treatment against EGFR involved in the spreading and survival of cancer cells.
- Safe to use
TheraCIM is given, it does not add toxicity to your other concurrent treatment. To date over 65,000 patients have used TheraCIM and only 2.3% of the patients have reported related-serious adverse events with the treatment, making TheraCIM the safest drug in its class targeting EGFR receptor.
- Long-term use
- Simple administration
- Can be used in children
- Approved in countries outside US, EU and Japan
- Wide experience use
TheraCIM is well tolerated even when it was used for longer periods beyond TheraCIM standard treatment (which is normally for 60 days).
Easy and effective administration time of 30-60 minutes, No premedication, No loading dose, No monitoring, and having standard dose per patients.
TheraCIM has been approved in several countries outside US, EU, Japan for glioma, which is a brain cancer in children arising from glial cells which are the most abundant cell types in the central nervous system.
TheraCIM has been approved in 25 countries outside US, EU and Japan, including China, India, Brazil, ASEAN and Latin America for head and neck cancer, glioma, esophageal, nasopharyngeal carcinoma and pancreatic cancer.
TheraCIM has been successfully given to more than 65,000 patients to date and based on over 130 publications in peer review journals, 92 clinical studies and approvals in 25 countries for multiple tumor types.